Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Palisade Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
PALI
Nasdaq
2836
www.palisadebio.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Palisade Bio, Inc.
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
- Feb 10th, 2025 1:45 pm
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
- Jan 29th, 2025 1:45 pm
Palisade Bio to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
- Jan 22nd, 2025 1:00 pm
Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis
- Jan 16th, 2025 1:00 pm
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan 3rd, 2025 10:20 pm
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board
- Dec 17th, 2024 1:30 pm
Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
- Dec 13th, 2024 9:05 pm
Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules
- Dec 12th, 2024 5:05 pm
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects
- Dec 3rd, 2024 1:15 pm
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)
- Nov 21st, 2024 1:15 pm
Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit
- Nov 14th, 2024 2:00 pm
Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108
- Nov 12th, 2024 1:45 pm
Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)
- Nov 7th, 2024 1:30 pm
Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis
- Oct 31st, 2024 12:30 pm
Palisade Bio Announces Abstract Accepted for Presentation at the American College of Gastroenterology’s (ACG) 2024 Annual Scientific Meeting
- Oct 15th, 2024 12:00 pm
Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)
- Oct 10th, 2024 12:30 pm
Palisade Bio to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
- Oct 8th, 2024 12:00 pm
Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis
- Sep 25th, 2024 12:00 pm
Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies
- Sep 16th, 2024 12:00 pm
Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification
- Sep 5th, 2024 12:00 pm
Scroll